US Patent Issued to MIRATI THERAPEUTICS on Sept. 23 for "Naphthyridine derivatives as PRC2 inhibitors" (California Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,421,228, issued on Sept. 23, was assigned to MIRATI THERAPEUTICS INC. (Princeton, N.J.).

"Naphthyridine derivatives as PRC2 inhibitors" was invented by John Michael Ketcham (San Diego), Aaron Craig Burns (San Diego) and Matthew Arnold Marx (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention."

The patent was filed on April 21,...